Mark Lackner - 03 Feb 2025 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Scientific Officer
Signature: /s/ Andrea Paul, attorney-in-fact for Mark Lackner
Issuer symbol: ZNTL
Transactions as of: 03 Feb 2025
Net transactions value: -$24,591
Form type: 4
Filing time: 05 Feb 2025, 18:32:31 UTC
Previous filing: 03 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+335,907	+176%	$0.000000	527,224	03 Feb 2025	Direct	F1
transaction	ZNTL	Common Stock	Sale	$24,591	-14,368	-2.7%	$1.71	512,856	03 Feb 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+124,714		$0.000000	124,714	03 Feb 2025	Common Stock	124,714	$1.68	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
F3	The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.